Suppr超能文献

Tectorigenin 通过激活 PPARγ 抑制肝内炎症和胆汁淤积来缓解肝内胆汁淤积。

Tectorigenin alleviates intrahepatic cholestasis by inhibiting hepatic inflammation and bile accumulation via activation of PPARγ.

机构信息

Department of Endocrinology, The Second Clinical Medical College, Jinan University (Shenzhen People's Hospital), Shenzhen, China.

First Teaching Hospital of Tianjin University of Traditional Chinese Medicine, Tianjin, China.

出版信息

Br J Pharmacol. 2021 Jun;178(12):2443-2460. doi: 10.1111/bph.15429. Epub 2021 Apr 16.

Abstract

BACKGROUND AND PURPOSE

Increasing evidence suggests that human cholestasis is closely associated with the accumulation and activation of hepatic macrophages. Research indicates that activation of PPARγ exerts liver protective effects in cholestatic liver disease (CLD), particularly by ameliorating inflammation and fibrosis, thus limiting disease progression. However, existing PPARγ agonists, such as troglitazone and rosiglitazone, have significant side effects that prevent their clinical application in the treatment of CLD. In this study, we found that tectorigenin alleviates intrahepatic cholestasis in mice by activating PPARγ.

EXPERIMENTAL APPROACH

Wild-type mice were intragastrically administered α-naphthylisothiocyanate (ANIT) or fed a diet containing 0.1% 3,5-diethoxycarbonyl-1,4-dihydrocollidine (DDC) to simultaneously establish an experimental model of intrahepatic cholestasis and tectorigenin intervention, followed by determination of intrahepatic cholestasis and the mechanisms involved. In addition, PPARγ-deficient mice were administered ANIT and/or tectorigenin to determine whether tectorigenin exerts its liver protective effect by activating PPARγ.

KEY RESULTS

Treatment with tectorigenin alleviated intrahepatic cholestasis by inhibiting the recruitment and activation of hepatic macrophages and by promoting the expression of bile transporters via activation of PPARγ. Furthermore, tectorigenin increased expression of the bile salt export pump (BSEP) through enhanced PPARγ binding to the BSEP promoter. In PPARγ-deficient mice, the hepatoprotective effect of tectorigenin during cholestasis was blocked.

CONCLUSION AND IMPLICATIONS

In conclusion, tectorigenin reduced the recruitment and activation of hepatic macrophages and enhanced the export of bile acids by activating PPARγ. Taken together, our results suggest that tectorigenin is a candidate compound for cholestasis treatment.

摘要

背景与目的

越来越多的证据表明,人类胆汁淤积症与肝巨噬细胞的积累和激活密切相关。研究表明,PPARγ 的激活对胆汁淤积性肝病 (CLD) 具有肝脏保护作用,特别是通过改善炎症和纤维化,从而限制疾病进展。然而,现有的 PPARγ 激动剂,如曲格列酮和罗格列酮,具有显著的副作用,阻止了它们在 CLD 治疗中的临床应用。在本研究中,我们发现,通过激活 PPARγ,葛根素减轻了小鼠的肝内胆汁淤积。

实验方法

野生型小鼠给予α-萘异硫氰酸酯 (ANIT) 灌胃或给予含 0.1%3,5-二乙氧羰基-1,4-二氢吡啶 (DDC) 的饮食,同时建立肝内胆汁淤积实验模型和葛根素干预模型,然后测定肝内胆汁淤积情况及相关机制。此外,给予 PPARγ 缺陷型小鼠 ANIT 和/或葛根素,以确定葛根素是否通过激活 PPARγ 发挥其肝脏保护作用。

主要结果

葛根素通过抑制肝巨噬细胞的募集和激活,促进胆汁转运体的表达,从而缓解肝内胆汁淤积。此外,葛根素通过增强 PPARγ 与 BSEP 启动子的结合,增加胆汁盐输出泵 (BSEP) 的表达。在 PPARγ 缺陷型小鼠中,葛根素在胆汁淤积时的肝保护作用被阻断。

结论和意义

总之,葛根素通过激活 PPARγ 减少肝巨噬细胞的募集和激活,增强胆汁酸的排泄。综上所述,我们的研究结果表明葛根素是一种治疗胆汁淤积的候选化合物。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验